Pages that link to "Q41363142"
Jump to navigation
Jump to search
The following pages link to Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. (Q41363142):
Displaying 40 items.
- Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes (Q24647904) (← links)
- Transfer of efficient anti-melanocyte T cells from vitiligo donors to melanoma patients as a novel immunotherapeutical strategy (Q24814910) (← links)
- Structures of MART-126/27–35 Peptide/HLA-A2 Complexes Reveal a Remarkable Disconnect between Antigen Structural Homology and T Cell Recognition (Q27647534) (← links)
- Direct T cell-tumour interaction triggers TH1 phenotype activation through the modification of the mesenchymal stromal cells transcriptional programme (Q33750137) (← links)
- A broadly applicable approach to T cell epitope identification: application to improving tumor associated epitopes and identifying epitopes in complex pathogens (Q34004266) (← links)
- A screening assay to identify agents that enhance T-cell recognition of human melanomas (Q34074758) (← links)
- Melanoma peptide vaccines: from preclinical background to clinical trials (Q34107773) (← links)
- Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma (Q34111789) (← links)
- Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer (Q34353878) (← links)
- HPV-E7 delivered by engineered exosomes elicits a protective CD8⁺ T cell-mediated immune response (Q35232797) (← links)
- Optimizing parameters for clinical-scale production of high IL-12 secreting dendritic cells pulsed with oxidized whole tumor cell lysate (Q35768996) (← links)
- Conditional superagonist CTL ligands for the promotion of tumor-specific CTL responses (Q35855820) (← links)
- Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients (Q36011425) (← links)
- Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma (Q36119828) (← links)
- Interleukin 2 restores CD3-zeta chain expression but fails to generate tumour-specific lytic activity in tumour-infiltrating lymphocytes derived from human colorectal hepatic metastases (Q36292335) (← links)
- Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35) (Q36367223) (← links)
- An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillanc (Q36375260) (← links)
- Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes (Q36470734) (← links)
- Cytotoxic T lymphocytes that recognize decameric peptide sequences of retinoblastoma binding protein 1 (RBP-1) associated with human breast cancer. (Q36619554) (← links)
- Frequency of MART-1/MelanA and gp100/PMel17-specific T cells in tumor metastases and cultured tumor-infiltrating lymphocytes (Q36835348) (← links)
- Functional heterogeneity of vaccine-induced CD8(+) T cells (Q36908627) (← links)
- Anti-tumor activity of cytotoxic T lymphocytes elicited with recombinant and synthetic forms of a model tumor-associated antigen (Q36914397) (← links)
- HLA associations in the antitumor response against malignant melanoma. (Q36924466) (← links)
- Dendritic Cells Infected with PoxvIn Vitro iruses Encoding MART-1/ Melan A Sensitize T Lymphocytes In Vitro (Q36924579) (← links)
- Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A (Q37003339) (← links)
- Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. (Q37360526) (← links)
- The CD8⁺ T Cell-Mediated Immunity Induced by HPV-E6 Uploaded in Engineered Exosomes Is Improved by ISCOMATRIXTM Adjuvant. (Q37539231) (← links)
- Surrogate in vitro activation of innate immunity synergizes with interleukin-7 to unleash rapid antigen-driven outgrowth of CD4+ and CD8+ human peripheral blood T-cells naturally recognizing MUC1, HER2/neu and other tumor-associated antigens (Q37706835) (← links)
- Accessing Epstein-Barr virus-specific T-cell memory with peptide-loaded dendritic cells. (Q39548736) (← links)
- T-cell recognition of self peptides as tumor rejection antigens (Q41197240) (← links)
- Cytolytic T lymphocyte responses of cancer patients to tumor-associated antigens (Q41202957) (← links)
- Immunotherapy I: Cyclosine gene transfer strategies (Q41349062) (← links)
- Human tumor antigens recognized by T-cells (Q41687574) (← links)
- 2L-PCA: a two-level principal component analyzer for quantitative drug design and its applications (Q42378453) (← links)
- High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals (Q42947076) (← links)
- Engineered exosomes emerging from muscle cells break immune tolerance to HER2 in transgenic mice and induce antigen-specific CTLs upon challenge by human dendritic cells (Q47215348) (← links)
- Towards the chemometric dissection of peptide--HLA-A*0201 binding affinity: comparison of local and global QSAR models. (Q51967888) (← links)
- Advanced model systems and tools for basic and translational human immunology (Q59126043) (← links)
- A phase I clinical study of vaccination of melanoma patients with dendritic cells loaded with allogeneic apoptotic/necrotic melanoma cells. Analysis of toxicity and immune response to the vaccine and of IL-10 -1082 promoter genotype as predictor of d (Q59216407) (← links)
- Monoclonal antibodies in cancer therapy (Q71759737) (← links)